Roche has reported a positive confirmatory trial readout for Lunsumio, a T-cell engaging bispecific antibody. The phase 3 study met its primary endpoint in earlier-line follicular lymphoma, according to a report from Fierce Pharma. No specific efficacy numbers or effect sizes were disclosed in the source.
The result marks the latest milestone for Roche's T-cell engager portfolio, which has been expanding across blood cancers. Because the source provides only this single trial update, there is no comparative data from other studies or competing therapies to weigh against the finding.
Lunsumio is already an established option in relapsed or refractory settings, and this earlier-line readout suggests it could move into a less advanced stage of treatment. Full results and regulatory implications are likely to follow in future presentations.